ConjuGon to present at Sachs-Bloomberg Global Biotech Forum

MADISON – The Sachs-Bloomberg Global Biotech Forum for Investing & Partnering has selected ConjuGon to present at its forum in Boston, April 1-2. The conference is designed to bring together promising biotechnology companies, leading investors and pharmaceutical companies.

The chance to raise venture capital on the coast is a welcome one, according to Sal Braico, chief operating officer at ConjuGon. "I think we're unlike a lot of Wisconsin companies … [we] talk with people on the coast as well as venture capitalists here."

The Sachs-Bloomberg Global Biotech Forum features panel discussions in fields such as value creation in biotechnology and technology transfer as well as various keynote speakers. A total of 50 companies will present. For ConjuGon and the other selected companies, attending the forum presents an opportunity to discuss their business plans with venture capitalists.

The selection process was based on a company's potential and investor interest, Braico said.

ConjuGon has raised more than $1.1 million in seed capital, including $700,000 from angel investors, and $290,000 in economic development loans from the Madison Development Corporation and the Wisconsin Department of Commerce. The company has also been awarded a $100,000 Small Business Innovation Research Phase I grant from the
National Science Foundation.

ConjuGon is a Madison-based company developing technologies to fight antibiotic-resistant bacteria.